Categories: 'thereCOVID-

There Are Few Good COVID Antivirals, but That Could Be Changing

Delta variant of the virus spreads rapidly, treatment options are limited. Two of the current best available treatments, monoclonal antibodies and the drug remdesivir, are given by infusion. Patients only benefit during the first week or so of infection, when the virus is still present and replicating in the body. These medications are expensive and often unavailable outside of large teaching hospitals. In many instances, patients are treated too late, after the disease has already shifted to a more dangerous hyperinflammatory state.

Doctors want to give pills that infected people can take conveniently at home when symptoms first appear. Toward that end, the Biden administration announced in June that it would spend more than $3 billion on a program aimed at developing next-generation antiviral therapies—not just for COVID but also for other viruses that pose a future threat.

In an interview with Scientific American, Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said he was cautiously optimistic that the new Antiviral Program for Pandemics (APP) would save lives and prevent surging hospitalizations. “It’s an ambitious program,” he said. “But if we can block the virus early on, then we can avoid the progression to advanced stages of the disease, which are so devastating to so many.”

Why is there still such a paucity of antivirals for COVID? Experts point to several factors. Antiviral research has been long neglected in general, and coronaviruses never garnered the sustained attention and funding that could have made more COVID treatments available sooner. “No one cared about coronaviruses,” says Timothy Sheahan, a virologist at the University of North Carolina at Chapel Hill. “Most of the coronaviruses that make people sick cause the common cold. And those that cause more severe disease were no longer considered a problem. The first SARS [severe acute respiratory syndrome] outbreak was over, and Middle East respiratory syndrome [MERS] wasn’t deemed a global threat.”

The COVID pandemic has now made new antiviral treatments a priority. But generating these therapies—especially direct-acting, orally administered drugs that inactivate viruses—is time-consuming. The reason monoclonal antibodies came along first is that scientists could simply follow the immune system’s lead and create synthetic versions of the natural antibodies that deflect the novel coronavirus, or SARS-CoV-2, from its host cell receptor in recovered patients. The goal of an antiviral pill is to stop the pathogen from replicating, but finding drugs that can do that without injuring the infected human cell is no easy task. Scientists start by screening thousands of compounds for their efficacy in targeting SARS-CoV-2 in cell culture. Promising candidates are then tested in animals—both to ensure that the drugs are not toxic and that they are not immediately destroyed in the body and reach tissues in the lungs and other organs in sufficient amounts. All this work takes place in high-level biosafety laboratories staffed by skilled workers, who are in short supply. “And then most of the compounds that work in cells ultimately fail in animal studies for lots of reasons,” says Sara Cherry, a microbiologist at the University of Pennsylvania’s Perelman School of Medicine. Cherry runs a biosafety lab at the university where researchers have so far screened 20,0000 compounds—including nearly every medication approved by the U.S. Food and Drug Administration—for anti-SARS-CoV-2 activity in isolated lung cells. Roughly 150 of these compounds have been selected for further evaluation in more complex lung models, “and then we’ll whittle down the top candidates for animal testing,” Cherry says.

Scientists at Emory University used this approach years ago to identify what is now the leading antiviral pill candidate for COVID: a drug called molnupiravir (also known as EIDD-2801) that was initially developed for influenza. Sheahan and other researchers, including virologists Mark Denison of Vanderbilt University Medical Center and Ralph Baric of the University of North Carolina at Chapel Hill, subsequently showed molnupiravir was effective against SARS-CoV-2 and other coronaviruses in human lung cells and infected mice. Molnupiravir has since been acquired by Merck and Ridgeback Biotherapeutics in Miami, and it is currently in clinical trials with patients experiencing mild to moderate COVID symptoms. A Merck spokesperson says that the company could file for an emergency use authorization for the drug in the U.S. later this year and in other countries in 2022.

Rachel Bender Ignacio, a physician-scientist at the Fred Hutchinson Cancer Research Center in Seattle, anticipates that the virus will develop less resistance against direct-acting small-molecule drugs such as molnupiravir than it has against monoclonal antibodies. Viruses are constantly mutating to avoid antibodies. Indeed, in June U.S.

Read More

News Bot

Share
Published by
News Bot
Tags: COVID-There

Recent Posts

5 ways Microsoft Edge is better than Chrome

No, seriously, Microsoft's web browser just keeps getting better. Today's Best Tech Deals Picked by…

51 mins ago

Walmart Onn Streaming Stick and Device reviews: Surprisingly great budget streamers

Walmart's cheap streamers should make Roku and Amazon sweat. Jared Newman / IDG Today's Best…

51 mins ago

X-Sense S21 Outdoor Security Camera review: Outstanding quality for a low price

This unassuming video camera is packed with features, including an LED spotlight for color night…

51 mins ago

The best pre-built PCs with AMD’s Ryzen 5300G, 5600G, or 5700G APUs

Beat the graphics card crunch with one of these pre-built PCs powered by AMD’s 5000-series…

51 mins ago

The best robot vacuum and mop combo is Narwal’s T10, and it’s $100 off at Amazon

If you purchase an independently reviewed product or service through a link on our website,…

54 mins ago

Android 12: Everything there is to know about Google’s next mobile OS

Android 12 is well and truly on the way. The world’s most-used operating system was…

54 mins ago